Rethinking Diabetes: A Weekly Review
Malattie Metaboliche e Diabetologia
Advances in Obesity and IBD Therapies
This week we discuss two groundbreaking studies: comparing semaglutide vs liraglutide for weight management in obesity, and risankizumab as a novel treatment for ulcerative colitis. Our hosts analyze the clinical implications of these findings.
Bibliography
1. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
Authors: Rubino DM, Greenway FL, Khalid U, et al.
Journal: JAMA, 2022 Jan 11
PMID: 35015037
DOI: 10.1001/jama.2021.23619
2. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
Authors: Louis E, Schreiber S, Panaccione R, et al.
Journal: JAMA, 2024 Sep 17
PMID: 39037800
DOI: 10.1001/jama.2024.12414
Authors: Rubino DM, Greenway FL, Khalid U, et al.
Journal: JAMA, 2022 Jan 11
PMID: 35015037
DOI: 10.1001/jama.2021.23619
2. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
Authors: Louis E, Schreiber S, Panaccione R, et al.
Journal: JAMA, 2024 Sep 17
PMID: 39037800
DOI: 10.1001/jama.2024.12414
